GF CSI All Share Health Care Index ETF(159938) Rises 1.89%, Sees Net Inflow of 25.6843 Million Yuan Over the Past 5 Trading Days

NewTimeSpace News, as of 13:13 on April 28, 2026, GF Pharmaceutical ETF (159938) rose 1.89%, with its latest quoted price at 0.65 yuan. Looking at a longer timeframe, as of April 27, 2026, GF Pharmaceutical ETF gained 5.13% over the past year. (The stocks listed above are merely index constituents and do not constitute any specific recommendation.)

In terms of liquidity, GF Pharmaceutical ETF recorded an intraday turnover rate of 1.04%, with a trading volume of 50.9419 million yuan. Over a longer horizon, as of April 27, the ETF's average daily turnover over the past month stood at 68.8066 million yuan.

Regarding scale, the latest AUM of GF Pharmaceutical ETF reached 4.774 billion yuan. (Data source: Wind)

In terms of capital inflows, the latest net outflow for GF Pharmaceutical ETF was 9.5334 million yuan. Looking at a longer timeframe, over the past five trading days, there were three days of net inflows, totaling 25.6843 million yuan, with an average daily net inflow of 5.1369 million yuan. (Data source: Wind)

Data shows that leveraged funds continue to position themselves. The net margin purchase amount for GF Pharmaceutical ETF on the previous trading day reached 2.1841 million yuan, and the latest margin balance stood at 28.5402 million yuan. (Data source: Wind)

As of April 27, GF Pharmaceutical ETF's net value increased by 5.47% over the past year. In terms of return capability, as of April 27, 2026, since its inception, the ETF achieved a highest single-month return of 22.34%, a longest consecutive gaining streak of eight months with a cumulative gain of 67.34%, a ratio of up months to down months of 72:64, and an average return of 5.58% during up months. As of April 27, 2026, since its inception, the ETF's annualized excess return over its benchmark was 1.28%.

In terms of drawdown, as of April 27, 2026, GF Pharmaceutical ETF's relative drawdown versus its benchmark since the beginning of the year was 0.10%.

In terms of fees, GF Pharmaceutical ETF has a management fee rate of 0.50% and a custody fee rate of 0.10%.

In terms of tracking accuracy, as of April 27, 2026, GF Pharmaceutical ETF's six-month tracking error was 0.010%.

From a valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI All-Share Health Care Index, which GF Pharmaceutical ETF tracks, is only 30.59 times, placing it at the 1.83rd percentile over the past year—meaning the valuation is lower than that of over 98.17% of the time in the past year, indicating a historically low level.

GF Pharmaceutical ETF closely tracks the CSI All-Share Health Care Index. The CSI All-Share Industry Select Index Series selects listed companies from the CSI All-Share Industry Index that meet certain liquidity and market capitalization screening criteria as index constituents, in order to reflect the overall performance of representative and investable listed company securities within each industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.